期刊文献+

福建地区汉族人群骨保护素基因位点多态性与急性冠脉综合征的相关性研究 被引量:3

Correlation between osteoprotegerin gene 209G/A, 245T/G and ll81G/C polymorphism and acute coronary syndromes in Han people of Fujian area
原文传递
导出
摘要 目的探讨福建地区汉族人群骨保护素(OPG)基因209G/A、245WG、1181G/C位点基因多态性与急性冠脉综合征(ACS)及其病变程度的相关性。方法采用前瞻性研究方法,选取2010年7月至2011年9月252例福建地区无血缘关系的汉族人为研究对象,纳入的184例ACS患者再根据冠状动脉(冠脉)造影结果分为单支病变组(60例)、双支病变组(68例)、多支病变组(54例),其中2例造影冠脉无狭窄;以68例健康体检者为对照。取静脉血提取DNA,采用Sanger测序法检测各组OPG基因209G/A、245WG、1181G/C位点多态性。分析ACS组与对照组之间以及ACS不同病变程度组之间209G/A、245WG、1181G/C各基因型和等位基因的分布频率以及基因多态性与ACS病变程度的关系。结果ACS组与对照组OPG209G/A、245WG位点基因型及等位基因分布均无明显差异;而1181G/C位点基因型分布[GG型:92(50.0%)比43(63.2%),CC型:26(14.1%)比0,GC型:66(35.9%)比25(36.8%),)(X2=11.240,P=0.004]、等位基因分布[等位基因G:250(67.9%)比111(81.6%),等位基因C:118(32.1%)比25(18.4%),X2=9.148,P=0.002]差异均有统计学意义。进一步分析发现,ACS单支病变组、双支病变组及多支病变组209G/A、245T/G及1181G/C位点分布比较均无明显差异。结论福建地区汉族人群OPG209G/A、245WG位点多态性与ACS无明显相关性;1181G/C位点基因多态性与ACS发病之间存在相关性,但与其病变程度无关。 Objective To explore the association of osteoprotegerin (OPG) gene polymorphisms 209G/A, 245T/G and 1181G/C in the Han population of Fujian province with acute coronary syndrome (ACS) and its severity. Methods A prospective study was conducted. Two hundred and fifty-two eases without sibship of Fujian Han people was enrolled from July 2010 tO September 2011, in which 68 healthy subjects as controls. One hundred and eighty-four patients with ACS were divided into three groups, 60 had one-vessel, 68 had two-vessel, and 54 had three-vessel lesion, 2 had not been found stegnosis. DNA was extracted from venous blood, different groups of OPG gene polymorphism was identified by Sanger Method. OPG 209G/A, 245T/G and 1181G/C genotype frequencies and allelic frequencies were analyzed between ACS subjects and normal subjects and among the three groups of ACS, and the relationship between gene polymorphisms and ACS severity. Results No significant differences were observed in the genotype and allelie frequencies of OPG gene 209G/A, 245T/G between the ACS and control groups. Significant differences were observed in the genotype and allelic frequencies of OPG gene 1181G/C between the ACS and control groups [ll81G/C GG. 92 (50.0%) vs. 43 (63.2%), CC.. 26 (14.1%) vs. 0, GC.. 66 (35.9%) vs. 25 (36.8%), X2= 11.240, P=0.004; allelic gene G: 250 (67.9%) vs. 111 (81.6%), allelic gene C: 118 (32.1%) vs. 25 (18.4%), X2= 9.148, P= 0.002 ]. No significant differences were observed in the genotype and allelic frequencies of OPG gene 209G/A, 245T/G and 1181G/C between those groups. Conclusions There were no significant difference in frequencies OPG genotype and allele in polymorphisms 209G/A, 245T/C between patients with ACS and control group in Han population of Fujian province. There were difference in frequencies OPG genotype and allele in polymorphisms 1181G/C between patients with ACS and control group, but it was not differently distributed among patients with single-, double-, or triple-vessel lesion.
出处 《中国危重病急救医学》 CAS CSCD 北大核心 2012年第12期730-733,共4页 Chinese Critical Care Medicine
基金 全军医学科技创新项目(09MA094)
关键词 骨保护素 急性冠脉综合征 基因多态性 Osteoprotegerin Acute coronary syndrome Gene polymorphism
  • 相关文献

参考文献12

  • 1Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2008,51 : 210-247.
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2166
  • 3Simonet WS, Lacey DL, Dunstan GR, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell, 1997,89:309-319.
  • 4Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 1997, 234: 137-142.
  • 5Soufi M, Schoppet M, Sattler AM, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab, 2004,89: 3764-3768.
  • 6Ueland T, Wilson SG, Amirul Islam FM, et al. A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clin Endocrinol (Oxf), 2009,71 : 828-833.
  • 7Celczyfiska Bajew L, Horst Sikorska W, Bychowiec B, et al. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol Pol, 2011,69:573-578.
  • 8谢钦菁,罗助荣.骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展[J].中华临床医师杂志(电子版),2011,5(10):2963-2966. 被引量:5
  • 9Price PA, June HH,Buckley JR,et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol,2001,21 : 1610-1616.
  • 10Bennett B J, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol,2006,26:2117-2124.

二级参考文献39

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2向光大,孙慧伶,赵林双,侯洁,乐岭,徐琳.1型糖尿病患者胰岛素治疗前后血浆护骨素的变化[J].中华医学杂志,2007,87(18):1234-1237. 被引量:32
  • 3Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 4Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 5Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 6CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 7Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 8Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 9Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.

共引文献2172

同被引文献39

  • 1谢钦菁,罗助荣.骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展[J].中华临床医师杂志(电子版),2011,5(10):2963-2966. 被引量:5
  • 2尚玉红,洪秀芳,吴鹏,马合木达.冠心病中医辨证与QT和JT离散度的关系[J].中国中西医结合急救杂志,2005,12(2):87-90. 被引量:17
  • 3权晓慧,朱秀英,武小薇,张瑞,李旋,胡元龙.绝经后妇女年龄、绝经年龄、绝经年限与腰椎和髋部骨密度的关系分析[J].中国骨质疏松杂志,2006,12(3):226-228. 被引量:14
  • 4Tsuda E,Goto M,Mochizuki S. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis[J].Biochemical and Biophysical Research Communications,1997,(1):137-142.doi:10.1006/bbrc.1997.6603.
  • 5中国中西医结合学会心血管专业委员会.冠心病中医辨证标准[J]中国中西医结合杂志,1991257.
  • 6Ueland T,Jemtland R,Godang K. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction[J].Journal of the American College of Cardiology,2004.1970-1976.
  • 7Omland T,Persson A,Ng L. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes[J].Circulation,2002.2913-2918.
  • 8Jono S,Ikari Y,Shioi A. Serumosteoprotegerin levels are associated with the presence and severity of coronary artery disease[J].Circulation,2002.1192-1194.
  • 9Schoppet M,Sattler AM,Schaefer JR. Increased osteoprotegerin serum levels in men with coronary artery disease[J].Journal of Clinical Endocrinology and Metabolism,2003.1024-1028.
  • 10Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J].American Journal of Cardiology,1983.606.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部